tiprankstipranks
Trending News
More News >
Extrawell Pharmaceutical Holdings Limited (HK:0858)
:0858
Hong Kong Market
Advertisement

Extrawell Pharmaceutical Holdings Limited (0858) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0858

Extrawell Pharmaceutical Holdings Limited

(0858)

Rating:61Neutral
Price Target:
HK$0.00
▼(-100.00% Downside)
The overall stock score is primarily influenced by the company's financial performance challenges, particularly in cash flow management and declining revenues. However, strong technical indicators and an attractive valuation provide some positive offset, suggesting potential for price appreciation if operational issues are addressed.

Extrawell Pharmaceutical Holdings Limited (0858) vs. iShares MSCI Hong Kong ETF (EWH)

Extrawell Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company DescriptionExtrawell Pharmaceutical Holdings Limited (0858) is a biotechnology company based in Hong Kong, primarily engaged in the development, manufacturing, and distribution of pharmaceutical products. The company operates in the sectors of prescription drugs, over-the-counter medications, and health supplements. Extrawell focuses on innovative drug delivery systems and generic pharmaceuticals, catering to both local and international markets with a robust portfolio of healthcare solutions.
How the Company Makes MoneyExtrawell Pharmaceutical Holdings Limited generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which include prescription medications and health supplements. The company engages in the manufacturing and distribution of generic drugs, which are sold to various healthcare providers and pharmacies. Additionally, Extrawell may earn income from partnerships with other healthcare firms for research and development initiatives, licensing agreements, and collaborations that enhance its product offerings. The company's revenue model is further supported by its ability to leverage economies of scale in production and a growing demand for affordable healthcare solutions, especially in emerging markets.

Extrawell Pharmaceutical Holdings Limited Financial Statement Overview

Summary
Extrawell Pharmaceutical faces significant challenges with declining revenues and cash flow issues, despite maintaining a stable balance sheet with low leverage. The company needs to address operational inefficiencies and improve cash flow management to enhance financial stability and growth prospects.
Income Statement
45
Neutral
Extrawell Pharmaceutical has experienced declining revenues over the past years, with a notable decrease of 7.23% in the latest year. Despite a positive net profit margin of 4.02% in the most recent period, the company has struggled with negative EBIT margins, indicating operational inefficiencies. The gross profit margin has also decreased, reflecting challenges in maintaining cost efficiency.
Balance Sheet
60
Neutral
The company maintains a relatively low debt-to-equity ratio of 0.11, suggesting prudent leverage management. However, the return on equity has been inconsistent, with a positive 16.68% in the latest year, indicating some profitability. The equity ratio remains stable, reflecting a solid capital structure.
Cash Flow
30
Negative
Extrawell Pharmaceutical's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate has been significantly negative, and the operating cash flow to net income ratio is also negative, indicating cash flow challenges despite reported net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue59.75M55.43M59.10M72.58M73.92M78.80M
Gross Profit25.70M21.87M28.78M31.14M37.56M42.57M
EBITDA118.09M255.11M-129.52M159.05M157.84M-97.48M
Net Income175.71M222.64M-162.95M129.26M130.59M-121.10M
Balance Sheet
Total Assets1.40B1.53B1.29B1.44B1.32B1.16B
Cash, Cash Equivalents and Short-Term Investments870.44M994.86M95.01M123.96M135.52M150.18M
Total Debt130.18M140.94M120.41M615.58M597.67M586.23M
Total Liabilities182.93M191.55M174.58M671.28M659.53M642.36M
Stockholders Equity1.22B1.33B1.11B769.36M653.29M518.15M
Cash Flow
Free Cash Flow1.61M-7.44M-4.89M-3.40M-11.23M-953.00K
Operating Cash Flow2.81M-4.37M-3.69M3.21M-1.60M-232.00K
Investing Cash Flow7.06M-9.38M2.04M-12.50M-9.63M-681.00K
Financing Cash Flow-6.48M-1.58M-6.50M-2.29M-1.80M-1.69M

Extrawell Pharmaceutical Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.12
Price Trends
50DMA
0.10
Positive
100DMA
0.07
Positive
200DMA
0.06
Positive
Market Momentum
MACD
<0.01
Positive
RSI
63.37
Neutral
STOCH
28.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0858, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.10, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 63.37 is Neutral, neither overbought nor oversold. The STOCH value of 28.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0858.

Extrawell Pharmaceutical Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
HK$298.75M1.3523.02%-6.21%
56
Neutral
HK$44.06M33.77-2.40%-40.37%-112.64%
51
Neutral
$7.82B-0.16-39.78%2.19%21.38%-1.56%
48
Neutral
HK$190.18M-8.71%2.54%33.33%
45
Neutral
HK$179.70M-26.80%-6.09%66.59%
44
Neutral
HK$264.68M-40.39%-43.73%-434.56%
36
Underperform
HK$161.78M-7.42%10.93%-159.62%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.13
0.09
225.00%
HK:8622
Huakang Biomedical Holdings Company Limited
0.38
0.19
100.00%
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.34
-0.62
-64.58%
HK:1498
PuraPharm Corp. Ltd.
0.45
-0.22
-32.84%
HK:1312
Kontafarma China Holdings Ltd
0.03
0.00
0.00%
HK:0911
Qianhai Health Holdings Ltd.
0.26
-0.04
-13.33%

Extrawell Pharmaceutical Holdings Limited Corporate Events

Extrawell Pharmaceutical Announces New Share Issuance
Aug 14, 2025

Extrawell Pharmaceutical Holdings Limited has announced the issuance of new shares under a general mandate. The company has entered into three separate subscription agreements with different subscribers, resulting in the conditional agreement to issue a total of 160,000,000 new shares at a price of HK$0.097 per share. This move is expected to slightly dilute the existing share capital but could provide the company with additional capital for its operations. The completion of these subscriptions is contingent upon certain conditions being met, and stakeholders are advised to exercise caution.

Extrawell Pharmaceutical Announces Annual General Meeting and Share Issuance Plans
Jul 28, 2025

Extrawell Pharmaceutical Holdings Limited has announced its upcoming annual general meeting scheduled for August 22, 2025. The meeting will address ordinary business matters such as the adoption of financial statements, re-election of directors, and re-appointment of auditors. Additionally, special business will include resolutions to authorize directors to allot and issue additional shares, with specific limitations on the number of shares. This announcement indicates the company’s ongoing efforts to manage its corporate governance and shareholder relations effectively.

Extrawell Pharmaceutical Establishes Nomination Committee Terms
Jul 3, 2025

Extrawell Pharmaceutical Holdings Limited has outlined the terms of reference for its Nomination Committee, which is tasked with ensuring the board’s structure, size, and diversity align with the company’s strategic goals. The committee’s responsibilities include assessing board composition, recommending director appointments, and supporting board performance evaluations, all aimed at enhancing corporate governance and strategic alignment.

Extrawell Pharmaceutical Reports Turnaround in Annual Results
Jun 30, 2025

Extrawell Pharmaceutical Holdings Limited reported its annual results for the year ended March 31, 2025, showing a significant turnaround with a profit of HK$223.5 million compared to a loss in the previous year. The improvement was driven by gains in other income and reduced selling and distribution expenses, despite a decrease in revenue and increased finance costs.

Extrawell Pharmaceutical Anticipates Significant Profit Turnaround
Jun 23, 2025

Extrawell Pharmaceutical Holdings Limited has announced a significant financial turnaround, expecting to report a profit between HK$215 million and HK$225 million for the year ended March 31, 2025, compared to a loss in the previous year. This improvement is primarily due to a gain from the fair value change of financial assets, specifically investments in convertible bonds, marking a positive shift in the company’s financial performance.

Extrawell Pharmaceutical Schedules Board Meeting for Annual Results Approval
Jun 17, 2025

Extrawell Pharmaceutical Holdings Limited has announced a board meeting scheduled for June 30, 2025, to approve the annual results for the fiscal year ending March 31, 2025. This meeting is crucial as it will determine the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 16, 2025